Billiontoone (NASDAQ:BLLN) Stock Rating Reaffirmed as Buy by BTIG Research

Billiontoone (NASDAQ:BLLN)‘s stock had its “buy” rating reiterated by equities researchers at BTIG Research in a research report issued on Thursday, Marketbeat.com reports. They currently have a $130.00 target price on the stock. BTIG Research‘s price objective would indicate a potential upside of 14.10% from the stock’s current price.

BLLN has been the subject of several other reports. Wall Street Zen cut Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Canaccord Genuity Group started coverage on Billiontoone in a report on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 target price on the stock. Zacks Research upgraded shares of Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, October 8th. Finally, Guggenheim lifted their target price on shares of Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a research report on Thursday, October 1st. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $126.88.

Billiontoone Price Performance

Billiontoone stock traded up $1.55 during mid-day trading on Thursday, reaching $113.94. The company had a trading volume of 993,248 shares, compared to its average volume of 507,007. Billiontoone has a 1 year low of $61.96 and a 1 year high of $150.44. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. The company has a market capitalization of $5.38 billion and a P/E ratio of 123.85. The stock’s 50-day simple moving average is $105.37 and its 200-day simple moving average is $97.15.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. The business had revenue of $109.45 million for the quarter. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. On average, equities analysts predict that Billiontoone will post 0.80 EPS for the current year.

Insider Activity at Billiontoone

In related news, CEO Oguzhan Atay sold 25,001 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $109.24, for a total value of $2,731,109.24. Following the completion of the transaction, the chief executive officer owned 16,667 shares of the company’s stock, valued at approximately $1,820,703.08. The trade was a 60.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Bosch John Roderick Ten sold 2,834 shares of the business’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $113.17, for a total transaction of $320,723.78. Following the completion of the transaction, the senior vice president directly owned 16,551 shares of the company’s stock, valued at $1,873,076.67. The trade was a 14.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 264,194 shares of company stock valued at $27,797,333 over the last quarter. Insiders own 50.22% of the company’s stock.

Institutional Investors Weigh In On Billiontoone

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Aberdeen Group plc purchased a new position in shares of Billiontoone during the third quarter valued at approximately $19,565,000. Three Bridge Wealth Advisors LLC purchased a new stake in Billiontoone in the 3rd quarter worth approximately $275,000. Penn Capital Management Company LLC raised its holdings in Billiontoone by 2.3% in the 3rd quarter. Penn Capital Management Company LLC now owns 132,636 shares of the company’s stock valued at $14,143,000 after acquiring an additional 3,034 shares during the last quarter. Parallel Advisors LLC raised its holdings in Billiontoone by 86.7% in the 3rd quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Finally, Provenance Wealth Advisors LLC purchased a new position in shares of Billiontoone during the 3rd quarter worth $56,000.

Billiontoone News Summary

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results beat expectations: BillionToOne reported earnings of $0.32 per share versus a $0.16 consensus estimate, while revenue also topped analyst expectations. Q3 earnings report
• Positive Sentiment: Higher 2026 revenue outlook and upcoming product: The company raised its full-year revenue guidance to $460 million–$470 million and plans to launch Northstar Clear on December 15, giving investors signs of growth and a near-term product catalyst. Outlook and product launch
• Positive Sentiment: Analysts remain constructive: JPMorgan raised its price target from $130 to $135 and maintained an Overweight rating; BTIG reaffirmed its Buy rating with a $130 target. JPMorgan price-target change
• Negative Sentiment: Several executives sold shares: The CEO, CTO and an SVP disclosed sales, including a substantial reduction in the CTO’s reported holdings. The transactions were conducted under pre-arranged Rule 10b5-1 plans, which may temper concerns but could still weigh on sentiment. Insider sale report

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.